JNJ-79635322, teclistamab clinical trials

A study comparing JNJ-79635322 and an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody in participants with relapsed or refractory multiple myeloma (Trilogy-4)

This study looks at a new injection called JNJ-79635322 for multiple myeloma that has come back or isn't responding to treatment. We're comparing it to another approved drug, teclistamab, to see if it helps patients aged 18 and over who have tried other therapies.